Eli Lilly and Co. announced Thursday, Dec. 18 that its experimental daily GLP-1 pill, orforglipron, successfully helped patients maintain significant weight loss after they stopped using popular injectable treatments like Wegovy and Zepbound.
Read MoreEli Lilly and Co. has launched a national campaign aimed at reducing the stigma surrounding obesity, using personal stories and visual symbolism to highlight the challenges faced by people living with the disease.
Read MoreEli Lilly and Co. is preparing a new direct-to-employer model that will allow companies to offer coverage for its obesity medications, including Zepbound, beginning in early 2026.
Read MoreIndianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company’s second-quarter earnings report, alongside results from a closely watched trial of its experimental weight-loss pill.
Read MoreThe prevalence of one of the most common cardiovascular conditions in the U.S. is significantly higher than previously estimated, underscoring the need for better prevention and treatment strategies.
Read MoreAdipo Therapeutics, LLC, a late pre-clinical biopharmaceutical company developing treatments for obesity and related metabolic disorders, announced the positive results for a key study demonstrating promising results using human tissue samples.
Read MoreThe U.S. Food and Drug Administration approved Eli Lilly and Company’s Zepbound injection, the first and only obesity treatment of its kind that activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 hormone receptors.
Read MoreObesity and overweight are estimated to have caused a staggering $9.3 billion reduction in Indiana’s economy in 2022, equivalent to 2% of the state’s gross domestic product, according to a report released by GlobalData Plc, a leading data and analytics company based in London.
Read More
